drugset / Trial / NCT00530907
Valproic Acid and Bevacizumab in Patients With Advanced Cancer
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of bevacizumab in combination with valproic acid that can be given to patients with advanced cancer that has not responded to standard treatment or where there is no standard treatment for the disease. The safety of this drug combination will also be studied.
Timeline
- Start
- 2007-06
- Primary completion
- 2013-11
- Completion
- 2013-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Background | Valproic Acid | Small molecule | 5.3 mg/kg | Oral |
Indications
No indication recorded.